SUMOylation of the lysine-less tumor suppressor p14ARF counters ubiquitylation-dependent degradation

p14ARF is a lysine-less tumor suppressor that enhances SUMOylation of its interactors. Although p14ARF is known to interact with the E2 SUMO conjugating enzyme UBC9, the link between ARF and SUMOylation is poorly understood and the potential impact of SUMOylation on p14ARF is unknown. Here we show that SUMO2 conjugates to the N-terminus of p14ARF and stabilizes it. Either depleting UBC9 or pharmacologically inhibiting SUMOylation, induces p14ARF degradation. In contrast, blocking ubiquitination or NEDDylation, with TAK-243 or MLN4924/Pevonedistat respectively, increases p14ARF SUMOylation and restores p14ARF levels when SUMOylation is blocked. Treatment with MLN4924 also causes p14ARF-dependent mRNA upregulation of the SUMOylation components SUMO1, SUMO2, and UBC9, globally augmenting SUMOylation. Finally, p14ARF contributes to MLN4924-driven cytotoxicity of prostate cancer cells. Our results provide evidence that, despite lacking lysine, p14ARF is SUMOylated and this modification is critical to counter ubiquitin driven degradation and establishes a new link between inhibition of NEDDylation and SUMOylation.

Authors

Institutions

Publication Details

Journal
Cell Death and Disease
Published
2025-07-12
DOI
https://doi.org/10.1038/s41419-025-07854-z
Citations
1
Primary Topic
Ubiquitin and proteasome pathways
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SUMOylation of the lysine-less tumor suppressor p14ARF counters ubiquitylation-dependent degradation

Rosa Barrio, Santiago Vidal, Haifeng Chen, María Blanquer et al.
1 citations
Cell Death and Disease
Ubiquitin and proteasome pathways
0.81
article

SUMOylation of the lysine-less tumor suppressor p14ARF counters ubiquitylation-dependent degradation

Rosa Barrio, Santiago Vidal, Haifeng Chen, María Blanquer, Anxo Vidal, Yanis Hichem Bouzaher, Dimitris P. Xirodimas, Rocío Seoane, Carmen Rivas, Ignacio Palmero, James D. Sutherland, Rod Bremner, Manuel Collado, Ahmed El Motiam, Rocío M Tolosa, Manuel S. Rodríguez, Beatriz Rodríguez-Lemus, José A Herrera-Gavilán
article en
1 citations

Abstract

p14ARF is a lysine-less tumor suppressor that enhances SUMOylation of its interactors. Although p14ARF is known to interact with the E2 SUMO conjugating enzyme UBC9, the link between ARF and SUMOylation is poorly understood and the potential impact of SUMOylation on p14ARF is unknown. Here we show that SUMO2 conjugates to the N-terminus of p14ARF and stabilizes it. Either depleting UBC9 or pharmacologically inhibiting SUMOylation, induces p14ARF degradation. In contrast, blocking ubiquitination or NEDDylation, with TAK-243 or MLN4924/Pevonedistat respectively, increases p14ARF SUMOylation and restores p14ARF levels when SUMOylation is blocked. Treatment with MLN4924 also causes p14ARF-dependent mRNA upregulation of the SUMOylation components SUMO1, SUMO2, and UBC9, globally augmenting SUMOylation. Finally, p14ARF contributes to MLN4924-driven cytotoxicity of prostate cancer cells. Our results provide evidence that, despite lacking lysine, p14ARF is SUMOylated and this modification is critical to counter ubiquitin driven degradation and establishes a new link between inhibition of NEDDylation and SUMOylation.

Cell Death and DiseaseVol. 16(1)
Centre National de la Recherche Scientifique (FR), University of Toronto (CA), Université de Montpellier (FR), Universidade de Santiago de Compostela (ES), Lunenfeld-Tanenbaum Research Institute (CA), Instituto de Investigaciones Biomédicas Sols-Morreale (ES), Centro Nacional de Biotecnología (ES), Center for Research in Molecular Medicine and Chronic Diseases (ES), CIC bioGUNE (ES), Laboratoire de Chimie de Coordination (FR), Sinai Health System (CA), Instituto de Investigación Sanitaria de Santiago (ES), Universidad Autónoma de Madrid (ES), Icahn School of Medicine at Mount Sinai (US)
Fundación Banco Santander, Ministerio de Ciencia, Innovación y Universidades, Instituto de Investigación Sanitaria de Santiago de Compostela
Good health and well-being
Openalex Percentile: Top 26%
Ubiquitin and proteasome pathways
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.